MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. - Wikidata - awgldk - TriplyDB

MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.

MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.

http://www.wikidata.org/entity/Q34276394

about

Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectives Hepatitis C virus protease inhibitor-resistance mutations: our experience and review Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus Therapy Recent Advances in Antiviral Therapy for Chronic Hepatitis C Direct anti-HCV agents Role of Marine Natural Products in the Genesis of Antiviral Agents New era for management of chronic hepatitis C virus using direct antiviral agents: A review Chronic hepatitis C: future treatment Modeling HCV disease in animals: virology, immunology and pathogenesis of HCV and GBV-B infections Structural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172 Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis Hepatitis C treatment: where are we now?Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection.Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor.Hepatitis C viral entry inhibitors prolong viral suppression by replication inhibitors in persistently-infected Huh7 cultures Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.Over-expression and characterization of NS3 and NS5A of Hepatitis C virus genotype 3a.Improving the Resistance Profile of Hepatitis C NS3/4A Inhibitors: Dynamic Substrate Envelope Guided Design The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.New therapeutic strategies in HCV: second-generation protease inhibitors.New horizons in hepatitis C antiviral therapy with direct-acting antivirals.The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection.Novel therapeutic approaches for hepatitis C.Antiviral therapy for chronic hepatitis C in 2014.Hepatitis C virus genotype 3: a genotype that is not 'easy-to-treat'.Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies.Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy.Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy.Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection.Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease Inhibitor Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C.Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C.Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients.

P2860

Q21265028-47C4B788-3B46-4378-ADD0-180DECB4301C Q24628717-A6A81564-4D7F-4759-9C8A-1EC99DFF29DD Q26700073-7C2381F9-E48D-42AD-AF77-E280D09C431D Q26750476-85C9B9BF-EE5C-4C2E-9CCE-CC9D616D07DA Q26767329-9ADB7F40-C8D9-463E-A117-5C81CFE50501 Q26796360-7BF70304-F459-41F8-9921-AC889742691D Q26800050-C0B65E3F-CAA8-4542-B189-8E54D9CBDC85 Q26824075-4ECCFEA4-89AE-4AD5-B40D-2EF691FAACDC Q27002381-18BF0A63-966E-4BDB-B775-29F785E42047 Q27703170-0175021A-7F55-4FB7-9E03-5C8D97E59DAD Q28070260-55F45820-030A-4F86-A075-DC361B19BCDF Q30378509-D4DC34D2-83AE-4482-8186-8D677F9ED241 Q31051529-E0756D9D-2C13-42E5-915D-5C77B20AFDF1 Q34411907-702062D5-9563-401A-872A-9F7128B9A4A3 Q34423056-72EEA607-3256-4602-95A9-7969F7D4EE7B Q34766299-69E4D2C8-A029-4BFA-AD58-3B10CDB2188E Q36182240-E2549EED-3B36-4170-A233-45870FE00D11 Q36290778-2CA5CF90-5EC5-4951-898F-AA470B621213 Q36667066-97A7AE2F-9BF3-4437-924C-CC849333181A Q36933403-19F3C85B-FE47-4C34-BC84-63DE8F4D8823 Q37348347-E1855B6E-B3D6-4000-8BB7-C05424F13681 Q37604079-E40E9ADE-348F-4B28-87D4-4B3E3EFF3DD8 Q37710140-BD071FA7-D01D-45EB-8DD7-B08F6018BDBB Q38071391-5AD8BB69-2BCF-4475-8D6A-2145597C48C5 Q38087250-CA3D82F6-21A8-47DD-92C9-3EDFC9A652C6 Q38113079-57EBF3EF-DCD9-4BE3-A954-1D5C6D39042B Q38152674-6E7286F9-B955-493B-AF16-834A500A5AAB Q38221090-7744F3E4-9025-45CB-ADAA-DBE522F96380 Q38249236-5A5183E3-5E8B-4D47-8510-7E77C45C9512 Q38265395-D941F391-C91C-4580-9BA5-85C67C7AE66B Q38295802-14E47E34-F4C2-443B-AA95-85F7930B22FA Q38381584-1ADA104A-10C7-48A8-BE3C-8F530B6ED8C7 Q38458110-AE428DEF-C335-4065-8DB5-001A653E51D0 Q38703524-F313EC37-D85D-426E-960C-9C64FA222627 Q38714156-D68D1E9B-A46E-460D-84EA-943F9C550202 Q38714640-5154329B-B075-4D97-A5F6-2A079197B0A6 Q38724091-C005A11C-025A-43E8-BA42-EC3ACA93018D Q38811486-2CF4D2C5-4B5E-4DB3-BC9B-6BA4F6214A12 Q38826176-614A8706-D9D1-487A-9756-9EB40C6AA5F9 Q38880996-E76F43CA-ABAC-4911-A9E5-E7C0D3F2CF8A

P2860

MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.

http://www.wikidata.org/entity/Q34276394

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

MK-5172, a selective inhibitor ...... otypes and resistant variants.

@ast

MK-5172, a selective inhibitor ...... otypes and resistant variants.

@en

MK-5172, a selective inhibitor ...... otypes and resistant variants.

@nl

type

label

MK-5172, a selective inhibitor ...... otypes and resistant variants.

@ast

MK-5172, a selective inhibitor ...... otypes and resistant variants.

@en

MK-5172, a selective inhibitor ...... otypes and resistant variants.

@nl

prefLabel

MK-5172, a selective inhibitor ...... otypes and resistant variants.

@ast

MK-5172, a selective inhibitor ...... otypes and resistant variants.

@en

MK-5172, a selective inhibitor ...... otypes and resistant variants.

@nl

P1433

Q34276394-61DB5E36-C9B4-4385-876B-D9C3068EBA65

P1476

Q34276394-0629D9FE-4D70-4015-B412-E52CD713D7B9

P2093

Q34276394-0007D50F-2BD4-4F84-89E4-DF4117AD3E99

Q34276394-073B157D-7081-4995-A1F2-E20C2799252F

Q34276394-084D6A1B-A876-45DD-8C80-BDD9FFEB6A49

Q34276394-0C3A5C3F-6412-4348-B028-73B0DD9B806A

Q34276394-0CE23706-10FF-42DE-AE5E-FC872AACEB60

Q34276394-17227F99-C473-43F7-BF8D-9C6E406C6B03

Q34276394-1C3E2CDA-22B9-47FB-B273-538F852A0D98

Q34276394-494D45D6-FF70-4A1B-96A5-41608B96D141

Q34276394-6164BD13-AEEA-4842-AAD2-FE1C07EFA0A9

Q34276394-701C06A0-5FAD-480E-9363-585F2628AEB1

P2860

Q34276394-0D9BDA4C-25D2-433F-8702-665E11573875

Q34276394-0E63BC89-FC3D-4A7C-AA09-F4D262F5D864

Q34276394-14BE3D1E-E0F0-4D66-8183-EC183C60BC4E

Q34276394-1C38C853-7388-44E1-AB85-450C0F38DEB0

Q34276394-3930CDDA-8A35-46A0-B00B-DA13CB443C91

Q34276394-39A1D3FA-C648-4E16-B9DF-854969848906

Q34276394-3D9FC4D9-2532-4BA3-8DC4-50858242F769

Q34276394-3DCE753F-C030-4E84-9CA1-03D597A3DF9C

Q34276394-44E9640C-A87C-45DF-A13A-3CC09C99AF56

Q34276394-46E94603-FAC5-4F67-91C8-D53A9536B3FA

P304

Q34276394-A49B3C93-45DC-434C-840E-74D66562F853

P31

Q34276394-A86A9F74-9CB1-4B3B-AECF-967967F89C45

P356

Q34276394-8BA2E911-4439-41A2-B218-1899E11370B1

P407

Q34276394-9096ED74-EA6B-48B4-AAEF-2A9CBF308015

P433

Q34276394-AA2315A8-1C10-4681-9A99-06DE0A122B3E

P478

Q34276394-FD31D0B1-DC5E-4D56-BFE1-612DEB7F70B8

P577

Q34276394-2C2E7F53-5EE8-431B-A36B-7BF5C15F3922

P5875

Q34276394-FAEDB7A1-4D1C-45D5-AEF2-0A8D5641E3B3

P698

Q34276394-9C4B12F4-3E6B-48DB-BDFB-79177AC15134

P932

Q34276394-86E4D0BB-60E7-421B-B0F9-9F91AED229B7

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

MK-5172, a selective inhibitor ...... otypes and resistant variants.

@en

P2093

Adam T Gates

http://www.w3.org/2001/XMLSchema#string

Aileen Soriano

http://www.w3.org/2001/XMLSchema#string

Carolyn McHale

http://www.w3.org/2001/XMLSchema#string

Christine Burlein

http://www.w3.org/2001/XMLSchema#string

Christine Fandozzi

http://www.w3.org/2001/XMLSchema#string

Daria J Hazuda

http://www.w3.org/2001/XMLSchema#string

David B Olsen

http://www.w3.org/2001/XMLSchema#string

Donald J Graham

http://www.w3.org/2001/XMLSchema#string

Edith Monteagudo

http://www.w3.org/2001/XMLSchema#string

Giuliano Claudio

http://www.w3.org/2001/XMLSchema#string

P2860

In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease

SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.

In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor

Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System

Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796

Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)

Robust Antiviral Efficacy upon Administration of a Nucleoside Analog to Hepatitis C Virus-Infected Chimpanzees

MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

P304

4161-4167

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00324-12

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225054416

http://www.w3.org/2001/XMLSchema#string

P698

22615282

http://www.w3.org/2001/XMLSchema#string

P932

3421554

http://www.w3.org/2001/XMLSchema#string